Compare Wahed FTSE USA Shariah ETF (HLAL) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Wahed FTSE USA Shariah ETF vs Pfizer Inc — how do they compare? Wahed FTSE USA Shariah ETF trades at $72.95, while Pfizer Inc trades at $26.26 (market cap $151.73B). The key difference: Pfizer Inc pays a 6.46% dividend while Wahed FTSE USA Shariah ETF pays none, and Wahed FTSE USA Shariah ETF is trading nearer its 52-week high, Pfizer Inc nearer its low. Which is the better fit depends on your goals.
| HLAL | PFE | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $73.60 | $28.56 |
52-Week Low | $55.52 | $23.60 |
Market Cap | — | $151.73B |
Volume | — | 29,869,932 |
Enterprise Value | — | $203.22B |
Dividend Yield | — | 6.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HLAL trades at $73.11 with a slight 0.19% daily gain, showing bullish technical momentum with strong moving average support. The stock lacks key valuation metrics (P/E, P/S, P/B) in current data, and a small dividend of $0.02 is scheduled for June 2026. Technical indicators show mixed signals with RSI suggesting potential overbought conditions near-term.
The outlook remains cautiously optimistic given bullish technical trends, but limited fundamental data and high RSI levels near 95 warrant monitoring. Key risks include reliance on technical momentum without clear valuation anchors, while institutional sentiment appears constructive based on moving average alignment.
Pfizer (PFE) trades at $27.05, up 1.16% with a bullish technical signal and consistent earnings beats in recent quarters. Revenue remains stable around $62-63 billion, though net income is projected to decline in 2026. The stock shows strong profitability margins and a solid balance sheet, but faces headwinds from patent expirations and competitive pressures.
The outlook is mixed: valuation multiples appear reasonable, and analyst consensus leans hold with a $27.86 target. Key risks include execution on pipeline catalysts and margin compression. Upside depends on successful drug launches and cost management amid a challenging revenue environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Wahed FTSE USA Shariah ETF
HLAL is an ETF that invests in Shariah-compliant US companies. It follows a rigorous screening process to exclude businesses involved in non-compliant activities like interest-based finance, alcohol, and gambling.
Read more on HLAL →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
